Literature DB >> 21841782

A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis.

Mourad Matmati1, Peggy Jacques, Jonathan Maelfait, Eveline Verheugen, Mirjam Kool, Mozes Sze, Lies Geboes, Els Louagie, Conor Mc Guire, Lars Vereecke, Yuanyuan Chu, Louis Boon, Steven Staelens, Patrick Matthys, Bart N Lambrecht, Marc Schmidt-Supprian, Manolis Pasparakis, Dirk Elewaut, Rudi Beyaert, Geert van Loo.   

Abstract

A20 (TNFAIP3) is a protein that is involved in the negative feedback regulation of NF-κB signaling in response to specific proinflammatory stimuli in different cell types and has been suggested as a susceptibility gene for rheumatoid arthritis. To define the contribution of A20 to rheumatoid arthritis pathology, we generated myeloid-specific A20-deficient mice and show that specific ablation of Tnfaip3 in myeloid cells results in spontaneous development of a severe destructive polyarthritis with many features of rheumatoid arthritis. Myeloid-A20-deficient mice have high levels of inflammatory cytokines in their serum, consistent with a sustained NF-κB activation and higher TNF production by macrophages. Destructive polyarthritis in myeloid A20 knockout mice was TLR4-MyD88 and IL-6 dependent but was TNF independent. Myeloid A20 deficiency also promoted osteoclastogenesis in mice. Together, these observations indicate a critical and cell-specific function for A20 in the etiology of rheumatoid arthritis, supporting the idea of developing A20 modulatory drugs as cell-targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841782     DOI: 10.1038/ng.874

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  31 in total

Review 1.  A20: central gatekeeper in inflammation and immunity.

Authors:  Beatrice Coornaert; Isabelle Carpentier; Rudi Beyaert
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

Review 2.  Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.

Authors:  Lisa G Criscione; E William St Clair
Journal:  Curr Opin Rheumatol       Date:  2002-05       Impact factor: 5.006

3.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors:  H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

Review 4.  RANKL-RANK signaling in osteoclastogenesis and bone disease.

Authors:  Teiji Wada; Tomoki Nakashima; Nishina Hiroshi; Josef M Penninger
Journal:  Trends Mol Med       Date:  2005-12-13       Impact factor: 11.951

5.  Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal Escherichia coli.

Authors:  E E Nieuwenhuis; M R Visser; A Kavelaars; P M Cobelens; A Fleer; W Harmsen; J Verhoef; L M Akkermans; C J Heijnen
Journal:  Arthritis Rheum       Date:  2000-11

6.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.

Authors:  David L Boone; Emre E Turer; Eric G Lee; Regina-Celeste Ahmad; Matthew T Wheeler; Colleen Tsui; Paula Hurley; Marcia Chien; Sophia Chai; Osamu Hitotsumatsu; Elizabeth McNally; Cecile Pickart; Averil Ma
Journal:  Nat Immunol       Date:  2004-08-29       Impact factor: 25.606

7.  The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals.

Authors:  Osamu Hitotsumatsu; Regina-Celeste Ahmad; Rita Tavares; Min Wang; Dana Philpott; Emre E Turer; Bettina L Lee; Nataliya Shiffin; Rommel Advincula; Barbara A Malynn; Catherine Werts; Averil Ma
Journal:  Immunity       Date:  2008-03       Impact factor: 31.745

8.  Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis.

Authors:  Lars Vereecke; Mozes Sze; Conor Mc Guire; Brecht Rogiers; Yuanyuan Chu; Marc Schmidt-Supprian; Manolis Pasparakis; Rudi Beyaert; Geert van Loo
Journal:  J Exp Med       Date:  2010-06-07       Impact factor: 14.307

9.  Fecal microbiota in early rheumatoid arthritis.

Authors:  Jussi Vaahtovuo; Eveliina Munukka; Mika Korkeamäki; Reijo Luukkainen; Paavo Toivanen
Journal:  J Rheumatol       Date:  2008-06-01       Impact factor: 4.666

Review 10.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.

Authors:  Peter C Taylor; Marc Feldmann
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

View more
  138 in total

Review 1.  Negative regulation of TLR signaling in myeloid cells--implications for autoimmune diseases.

Authors:  Jessica A Hamerman; Jessica Pottle; Minjian Ni; Yantao He; Zhong-Yin Zhang; Jane H Buckner
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

2.  T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways.

Authors:  Kohei Hosokawa; Sachiko Kajigaya; Keyvan Keyvanfar; Wangmin Qiao; Yanling Xie; Danielle M Townsley; Xingmin Feng; Neal S Young
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

Review 3.  Human Leukocyte Antigen-Disease Associations in Rheumatoid Arthritis.

Authors:  Vincent van Drongelen; Joseph Holoshitz
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

Review 4.  Genetic insights into common pathways and complex relationships among immune-mediated diseases.

Authors:  Miles Parkes; Adrian Cortes; David A van Heel; Matthew A Brown
Journal:  Nat Rev Genet       Date:  2013-08-06       Impact factor: 53.242

5.  Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-κB.

Authors:  Jakob Voelkl; Rashad Tuffaha; Trang T D Luong; Daniel Zickler; Jaber Masyout; Martina Feger; Nicolas Verheyen; Florian Blaschke; Makoto Kuro-O; Andreas Tomaschitz; Stefan Pilz; Andreas Pasch; Kai-Uwe Eckardt; Juergen E Scherberich; Florian Lang; Burkert Pieske; Ioana Alesutan
Journal:  J Am Soc Nephrol       Date:  2018-04-13       Impact factor: 10.121

Review 6.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death.

Authors:  Dimitry Ofengeim; Junying Yuan
Journal:  Nat Rev Mol Cell Biol       Date:  2013-10-16       Impact factor: 94.444

7.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

8.  A20 edits ubiquitin and autoimmune paradigms.

Authors:  Flavius Martin; Vishva M Dixit
Journal:  Nat Genet       Date:  2011-08-29       Impact factor: 38.330

Review 9.  [Novel molecular mechanisms in the pathophysiology of psoriatic arthritis].

Authors:  D Simon; E Kampylafka; A J Hueber
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

Review 10.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.